Illumina forecasts 2026 EPS of $5.40-$5.45 while raising revenue outlook to $4.64B-$4.66B (NASDAQ:ILMN)

seekingalpha.com · 2026-10-29

Illumina Q3 2026 earnings: raised guidance, strong NovaSeq X demand, and clinical sequencing growth.

TickrTrends take: Illumina's raised revenue guidance and improved earnings outlook for 2026 suggest the company expects meaningful growth ahead, yet TickrTrends currently assesses the stock as overvalued despite these positive forecasts. For valuation-focused investors, the key question becomes whether this forward guidance justifies the company's current market price relative to its projected earnings and revenue growth rates. Readers should monitor how the market reprices ILMN if management continues to deliver on or exceed these updated targets, as consistent execution could eventually align the stock's valuation with its growth trajectory.

Read the full story at seekingalpha.com →